In 2008, the year after Mylan purchased the rights to the EpiPen, the company’s lobbying budget topped a million dollars, according to data maintained by the Center for Responsive Politics.
By comparison, in 2007, that same lobbying budget was much closer to a quarter of a million.
In 2013, as Mylan was in the process of spending $1.5 million lobbying its members, Congress passed the School Access to Emergency Epinephrine Act.
The amount EpiPen's parent company spent on lobbying has increased over the years.
The law would allow schools across the country to carry epinephrine auto-injectors and administer a dosage to students who appear to be having a life-threatening allergic reaction.
Today 49 states allow schools to stock injectable epinephrine. Colorado passed its law in 2013.
While the laws are generally heralded for saving lives, they have also allowed Mylan to increase its brand awareness in a market that has grown decidedly void of any serious competitors.
“If you look at it strictly from a brand awareness and marketing standpoint, it was brilliant,” said Bud Bilanch, who once worked for a giant pharmaceutical company and now teaches at the Daniels College of Business at the University of Denver.
Yet Mylan didn’t stop with just changing laws.
The federal government now requires all payments by pharmaceutical companies to doctors be publicly disclosed.
RELATED: EpiPen maker to offer discounts after price hike firestorm
RELATED: Mylan says it will expand programs that lower EpiPen costs
RELATED: Massive price increases on EpiPens raise alarm
The requirement provides a window into the world of Mylan as it tried to befriend doctors with the power to recommend the product to patients.
In 2013, Mylan handed out $685,000 in EpiPen-related payments and giveaways to doctors across the United States. In 2014, the company upped the number to $1,158,000. Last year, Mylan distributed $1,208,000 - an increase in payments of nearly 70 percent.
Senators Chuck Grassley (R-IA) and Patrick Leahy (D-VT) have taken $17,000 each.
Some of those doctors started showing up on television news programs talking about allergies and the benefits of EpiPens. Few were ever questioned about their payments from Mylan.
Most of the payments were small, but in 2015, 124 doctors received more than $1000 a piece. Some doctors received higher payments since 2013, several doctors reported receiving multiple payments that added up to more than $50,000.
This year, according to data from Kantar Media, Mylan also spent at least $7,000,000 pushing a television ad titled “Face Your Risk” designed to capture a first-hand account of anaphylactic shock.
All while the price of EpiPens continued to increase. Mylan increased the cost nearly 400 percent since purchasing EpiPen in 2007.